Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutationdiversity, ductility, and destiny

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 807-814

  Suda, Kenichi ^a   Mizuuchi, Hiroshi ^a   Maehara, Yoshihiko ^a   Mitsudomi, Tetsuya ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KINDAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acquired resistance; EGFR mutation; Molecular target therapy; Non small cell lung cancer; Predictive factors

Indexed keywords

CRK LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHIONINE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; THREONINE;

CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; DOWN REGULATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERANCE; EARLY INTERVENTION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE AMPLIFICATION; GENE MUTATION; GENETIC CODE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SECONDARY GENE MUTATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84867991219     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9391-7     Document Type: Review

References (55)

1. Pao, W.; & Girard, N. (2011). New driver mutations in non-small-cell lung cancer. The Lancet Oncology, 12, 175-180.
2. Weinstein, I. B. (2002). Cancer. Addiction to oncogenesthe Achilles heal of cancer. Science, 297, 63-64.
3. Suda, K.; Tomizawa, K.; & Mitsudomi, T. (2010). Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 29, 49-60.
4. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology, 11, 121-128.
5. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine, 362, 2380-2388.
6. Zhou, C.; Wu, Y. L.; Chen, G.; Feng, J.; Liu, X. Q.; Wang, C.; et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology, 12, 735-742.
7. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13, 239-246.
8. Jackman, D.; Pao, W.; Riely, G. J.; Engelman, J. A.; Kris, M. G.; Janne, P. A.; et al. (2010). Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology, 28, 357-360.
9. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 352, 786-792.
10. Blencke, S.; Ullrich, A.; & Daub, H. (2003). Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. Journal of Biological Chemistry, 278, 15435-15440.
11. Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Solomon, S. B.; Zakowski, M. F.; et al. (2011). Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research, 17, 1169-1180.
12. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; et al. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105, 2070-2075.
13. Chmielecki, J.; Foo, J.; Oxnard, G. R.; Hutchinson, K.; Ohashi, K.; Somwar, R.; et al. (2011). Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine, 3, 90ra59.
14. Suda, K.; Onozato, R.; Yatabe, Y.; & Mitsudomi, T. (2009). EGFR T790M mutation: a double role in lung cancer cell survival? Journal of Thoracic Oncology, 4, 1-4.
15. Oxnard, G. R.; Arcila, M. E.; Sima, C. S.; Riely, G. J.; Chmielecki, J.; Kris, M. G.; et al. (2011). Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research, 17, 1616-1622.
16. Uramoto, H.; Yano, S.; & Tanaka, F. (2012). T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI. Lung Cancer, 76, 129-130.
17. Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.; Zakowski, M. F.; et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research, 12, 6494-6501.
18. Costa, D. B.; Halmos, B.; Kumar, A.; Schumer, S. T.; Huberman, M. S.; Boggon, T. J.; et al. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Medicine, 4, 1669-1679. discussion 80.
19. Bean, J.; Riely, G. J.; Balak, M.; Marks, J. L.; Ladanyi, M.; Miller, V. A.; et al. (2008). Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research, 14, 7519-7525.
20. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-1043.
21. Sequist, L. V.; Waltman, B. A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A. B.; Fidias, P.; et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3, 75ra26.
22. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; & Mitsudomi, T. (2009). Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. Journal of Thoracic Oncology, 4, 5-11.
23. Tanizaki, J.; Okamoto, I.; Okamoto, K.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; et al. (2011). MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. Journal of Thoracic Oncology, 6, 1624-1631.
24. Yamamoto, C.; Basaki, Y.; Kawahara, A.; Nakashima, K.; Kage, M.; Izumi, H.; et al. (2010). Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Research, 70, 8715-8725.
25. Suda, K.; Tomizawa, K.; Osada, H.; Maehara, Y.; Yatabe, Y.; Sekido, Y.; et al. (2012). Conversion from the oncogene addiction to drug addiction by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 76, 292-299.
26. Uramoto, H.; Shimokawa, H.; Hanagiri, T.; Kuwano, M.; & Ono, M. (2011). Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer, 73, 361-365.
27. Cheung, H. W.; Du, J.; Boehm, J. S.; He, F.; Weir, B. A.; Wang, X.; et al. (2011). Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discovery, 1, 608-625.
28. Yano, S.; Wang, W.; Li, Q.; Matsumoto, K.; Sakurama, H.; Nakamura, T.; et al. (2008). Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Research, 68, 9479-9487.
29. Yano, S.; Yamada, T.; Takeuchi, S.; Tachibana, K.; Minami, Y.; Yatabe, Y.; et al. (2011). Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. Journal of Thoracic Oncology, 6(12), 2011-2017.
30. Bivona, T. G.; Hieronymus, H.; Parker, J.; Chang, K.; Taron, M.; Rosell, R.; et al. (2011). FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 471, 523-526.
31. Liu, D.; Huang, C.; Kameyama, K.; Hayashi, E.; Yamauchi, A.; Kobayashi, S.; et al. (2001). E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. The Annals of Thoracic Surgery, 71, 949-954. discussion 54-5.
32. Bremnes, R. M.; Veve, R.; Gabrielson, E.; Hirsch, F. R.; Baron, A.; Bemis, L.; et al. (2002). High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. Journal of Clinical Oncology, 20, 2417-2428.
33. Yang, J.; Mani, S. A.; Donaher, J. L.; Ramaswamy, S.; Itzykson, R. A.; Come, C.; et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927-939.
34. Kang, Y.; & Massague, J. (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. Cell, 118, 277-279.
35. Chung, J. H.; Rho, J. K.; Xu, X.; Lee, J. S.; Yoon, H. I.; Lee, C. T.; et al. (2011). Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer, 73, 176-182.
36. Suda, K.; Tomizawa, K.; Fujii, M.; Murakami, H.; Osada, H.; Maehara, Y.; et al. (2011). Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. Journal of Thoracic Oncology, 6, 1152-1161.
37. Yao, Z.; Fenoglio, S.; Gao, D. C.; Camiolo, M.; Stiles, B.; Lindsted, T.; et al. (2010). TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 107, 15535-15540.
38. Chang, T. H.; Tsai, M. F.; Su, K. Y.; Wu, S. G.; Huang, C. P.; Yu, S. L.; et al. (2011). Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. American Journal of Respiratory and Critical Care Medicine, 183, 1071-1079.
39. Xie, M.; Zhang, L.; He, C. S.; Xu, F.; Liu, J. L.; Hu, Z. H.; et al. (2012). Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of Cellular Biochemistry, 113(5), 1501-1513.
40. Inukai, M.; Toyooka, S.; Ito, S.; Asano, H.; Ichihara, S.; Soh, J.; et al. (2006). Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Research, 66, 7854-7858.
41. Maheswaran, S.; Sequist, L. V.; Nagrath, S.; Ulkus, L.; Brannigan, B.; Collura, C. V.; et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine, 359, 366-377.
42. Turke, A. B.; Zejnullahu, K.; Wu, Y. L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; et al. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 17, 77-88.
43. Suda, K.; Murakami, I.; Katayama, T.; Tomizawa, K.; Osada, H.; Sekido, Y.; et al. (2010). Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clinical Cancer Research, 16, 5489-5498.
44. Ogino, A.; Kitao, H.; Hirano, S.; Uchida, A.; Ishiai, M.; Kozuki, T.; et al. (2007). Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Research, 67, 7807-7814.
45. Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Xiao, Y.; Capelletti, M.; Rogers, A.; et al. (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene, 29, 2346-2356.
46. Sharma, S. V.; Lee, D. Y.; Li, B.; Quinlan, M. P.; Takahashi, F.; Maheswaran, S.; et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141, 69-80.
47. Fan, W.; Tang, Z.; Yin, L.; Morrison, B.; Hafez-Khayyata, S.; Fu, P.; et al. (2011). MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Research, 71, 4494-4505.
48. Ng, K. P.; Hillmer, A. M.; Chuah, C. T.; Juan, W. C.; Ko, T. K.; Teo, A. S.; et al. (2012). A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 18, 521-528.
49. Kurata, T.; Tamura, K.; Kaneda, H.; Nogami, T.; Uejima, H.; Asai Go, G.; et al. (2004). Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Annals of Oncology, 15, 173-174.
50. Yano, S.; Nakataki, E.; Ohtsuka, S.; Inayama, M.; Tomimoto, H.; Edakuni, N.; et al. (2005). Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology Research, 15, 107-111.
51. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; et al. (2011). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. The New England Journal of Medicine, 363, 1734-1739.
52. Katayama, R.; Shaw, A. T.; Khan, T. M.; Mino-Kenudson, M.; Solomon, B. J.; Halmos, B.; et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Science Translational Medicine, 4, 120ra17.
53. Yoshida, T.; Okamoto, I.; Okamoto, W.; Hatashita, E.; Yamada, Y.; Kuwata, K.; et al. (2010). Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Science, 101, 167-172.
54. Kobayashi, N.; Toyooka, S.; Soh, J.; Yamamoto, H.; Dote, H.; Kawasaki, K.; et al. (2011). The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer, 75, 161-166.
55. Ju, L.; Zhou, C.; Li, W.; Yan, L. (2010). Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Journal of Cellular Biochemistry, 111, 1565-1574.